Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus

医学 安慰剂 不利影响 系统性红斑狼疮 内科学 随机对照试验 红斑狼疮 蛋白尿 强的松 临床试验 免疫学 疾病 抗体 肾 替代医学 病理
作者
Richard Furie,Ian N Bruce,Thomas Dörner,Manuel Gustavo Leon,Piotr Leszczyński,Murray B. Urowitz,Birgit Haier,Teri Jimenez,Claire Brittain,Jiajun Liu,Catherine Barbey,C. Stach
出处
期刊:Rheumatology [Oxford University Press]
卷期号:60 (11): 5397-5407 被引量:82
标识
DOI:10.1093/rheumatology/keab381
摘要

Abstract Objective To evaluate the dose–response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE. Methods Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A or ≥2 BILAG B domain scores), receiving stable CS (≤40 mg/day prednisone-equivalent), antimalarial or immunosuppressant drugs were included. Patients with stable LN (proteinuria ≤2 g/day) not receiving high-dose CS or CYC were permitted entry. Randomized patients received placebo or i.v. DZP (6/24/45 mg/kg) and standard-of-care (SOC) treatment every 4 weeks to week 24, after which patients received only SOC to week 48. The primary objective was to establish a dose–response relationship based on week 24 BILAG-Based Composite Lupus Assessment (BICLA) responder rates. Results All DZP groups exhibited improvements in clinical and immunological outcomes vs placebo at week 24; however, BICLA responder rates did not fit pre-specified dose–response models [best-fitting model (Emax): P = 0.07]. Incidences of serious treatment-emergent adverse events across DZP groups were low and similar to placebo. Following DZP withdrawal, SLEDAI-2K, physician’s global assessment (PGA), BILAG, and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores stabilized; BICLA and SLE Responder Index (SRI-4) responder rates declined (likely due to interventions with disallowed escape medications), BILAG flares increased, and immunologic parameters returned towards baseline. Conclusions Although the primary objective was not met, DZP appeared to be well tolerated, and patients exhibited improvements across multiple clinical and immunological measures of disease activity after 24 weeks relative to placebo. The potential clinical benefit of DZP warrants further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
twebery完成签到,获得积分10
2秒前
ff完成签到 ,获得积分10
3秒前
啊泽ovo完成签到,获得积分10
4秒前
123完成签到,获得积分10
4秒前
5秒前
罗春燕完成签到 ,获得积分10
6秒前
6秒前
leehoo完成签到,获得积分10
6秒前
沉静野狼完成签到,获得积分10
7秒前
cheng完成签到 ,获得积分10
7秒前
复杂芷文完成签到,获得积分10
8秒前
勤恳的猫完成签到,获得积分10
8秒前
铁头霸霸完成签到 ,获得积分10
9秒前
乐乐乐完成签到,获得积分10
9秒前
陈鹿华完成签到 ,获得积分10
9秒前
9秒前
ncuwzq完成签到,获得积分0
10秒前
内向鼠标完成签到 ,获得积分10
11秒前
机灵的寻芹完成签到,获得积分10
11秒前
keyanxiaobaishu完成签到 ,获得积分10
11秒前
502s完成签到,获得积分10
12秒前
卷毛君完成签到,获得积分10
12秒前
14秒前
14秒前
whandzxl完成签到,获得积分10
14秒前
NexusExplorer的应助被小天采纳,获得10
15秒前
toto完成签到 ,获得积分10
15秒前
15秒前
binban128完成签到,获得积分10
16秒前
言希完成签到,获得积分10
16秒前
happyou发布了新的文献求助10
16秒前
王一硕完成签到 ,获得积分10
18秒前
赘婿的应助被科研小将采纳,获得10
18秒前
Janus完成签到,获得积分10
20秒前
赘婿的应助被卷毛君采纳,获得10
20秒前
Zhao完成签到 ,获得积分10
21秒前
21秒前
cloud完成签到 ,获得积分10
21秒前
sss完成签到,获得积分10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923